Remedium Capital Partners
WEST PALM BEACH, FLfiles as Remedium Capital Partners, LLC
$452m in 6 US stocks at the end of 30 June 2026. The top 10 are 100.0% of the money. It changed about 9.8% of the portfolio this quarter.
Value
$452m
Stocks
6
Top 10 share
100.0%
Turnover
9.8%
What changed this quarter
New
Bought for the first time this quarter.
- Crescent BiopharmaCBIO1.4% of the fund
Added
Bought more of a stock they already held.
None this quarter.
Cut
Sold some of their stake.
None this quarter.
Sold out
Sold their entire stake.
Holdings
- Apogee TherapeuticsAPGE
- Share
- 17.2%
- Value
- $78m
- Shares
- 586,691
Held
- Damora Therapeutics
- Share
- 11.8%
- Value
- $53m
- Shares
- 2,045,473
Held
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Oruka TherapeuticsORKA | 33.0% | $149m | 1,565,661 | Held |
| Spyre TherapeuticsSYRE | 28.8% | $130m | 1,464,169 | Held |
| Apogee TherapeuticsAPGE | 17.2% | $78m | 586,691 | Held |
| Damora Therapeutics | 11.8% | $53m | 2,045,473 | Held |
| Jade BiosciencesJBIO | 7.8% | $35m | 1,577,750 | Held |
| Crescent BiopharmaCBIO | 1.4% | $7m | 361,250 | New |
Over time and by industry
Value over time
Dec '25
Jun '26
Value is up 165.3% since 31 December 2025.
Where the money is
Health care88.2%
Other11.8%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.